Adline Ghazi, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1609033869
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Eli Lilly at 30.1% of the total. Reporting peaked in 2024 at $1,924 and has fallen 87.2% since, to $247 in 2025.
Across 116 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$1K
- Novo Nordisk AS$1K
- Lilly USA, LLC$554
- Novo Nordisk$240
- Boehringer Ingelheim$198
- Corcept Therapeutics$163
- plus $902 from 17 others
Across 295 payments — averaging $4276.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$933K
- Novo Nordisk AS$158K
- Novartis$106K
- Boehringer Ingelheim Pharma GmbH & Co.kg$40K
- Janssen Research & Development, LLC$16K
- Boehringer Ingelheim International GmbH$9K
What the payments were for
- Travel & lodging$1,83240%
- Food & beverage$2,68159%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 21 | $1,362 |
| Novo Nordisk AS | 6 | $1,106 |
| Lilly USA, LLC | 28 | $554 |
| Novo Nordisk | 11 | $240 |
| Boehringer Ingelheim | 7 | $198 |
| Corcept Therapeutics | 7 | $163 |
| Radius Health, Inc. | 3 | $141 |
| Dexcom, Inc. | 7 | $140 |
| Tandem Diabetes Care, Inc. | 4 | $76 |
| Sanofi-aventis U.S. LLC | 3 | $69 |
| Amgen | 1 | $66 |
| Medtronic(2 entities) | 3 | $63 |
| Novartis | 2 | $55 |
| Insulet Corporation | 3 | $44 |
| Abbott | 2 | $43 |
| BETA Bionics, Inc. | 1 | $43 |
| BD | 1 | $39 |
| Embecta Corp. | 1 | $33 |
| Bayer | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| AstraZeneca | 1 | $17 |
| AbbVie | 1 | $17 |
How this compares
$4,525 in reported general payments places this provider in the 65th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 311 | $530,614 |
| TrulicityDulaglutide | 122 | $180,776 |
| MounjaroTirzepatide | 142 | $180,640 |
| JardianceEmpagliflozin | 129 | $176,626 |
| TymlosAbaloparatide | 14 | $50,501 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $38,932 |
| FarxigaDapagliflozin Propanediol | 33 | $35,626 |
| RybelsusSemaglutide | 20 | $28,348 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $26,042 |
| JanuviaSitagliptin Phosphate | 13 | $20,102 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $17,764 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $16,378 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 36 | $11,959 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $10,082 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $8,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $240 | $558,962331 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $554 | $367,071275 claims |
| Boehringer IngelheimJardiance | $198 | $176,626129 claims |
| Radius Health, Inc.Tymlos | $141 | $50,50114 claims |
| AstraZenecaFarxiga | $17 | $35,62633 claims |
| AbbVieSynthroid | $17 | $2,46223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Qudsia HussainWashington$9K
- Jerold ShareWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.